M
Mass General Brigham | MGB MGH Nagrebetsky
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
SPG302
Parent organization
This site is a part of Mass General Brigham
Curious how this site stacks up to its peers?
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
2 of 13 total trials
Atrial fibrillation (AF) is the most preventable cause of stroke. However, despite widely available risk stratification tools, numerous options for o...
Begins enrollment in 2 months
Atrial Fibrillation
Stroke
Behavioral: Alert-based computerized decision support
The first-in-human Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SPG302 in healthy...
Enrolling
Amyotrophic Lateral Sclerosis
Drug: Placebo
Drug: SPG302
Trial sponsors
H
S
Clinical trials
Research sites
Resources
Legal
© Copyright 2024 Veeva Systems